PARP Inhibitors Have Acceptable Toxicity Profiles and Have Shown Efficacy in Treatment of Ovarian Cancer
Olaparib plus Bevacizumab Has Been Approved as Maintenance Therapy for Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
Oral treatments for ovarian cancer can be taken at home, in a sequestered environment that may minimize undue risks for patients. Results from a randomized phase 3 study suggest oral PARP inhibitor therapy has improved efficacy when compared with intravenous chemotherapy.
Results 1 - 5 of 5